# The Absorption, Metabolism and Excretion of [14C]D-0316 in Human

> **NCT04464551** · PHASE1 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Advanced or Metastatic Non-small Cell Lung

## Interventions

- **DRUG:** [14C]D-0316 suspension

## Key facts

- **NCT ID:** NCT04464551
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-05
- **Primary completion:** 2021-08
- **Final completion:** 2021-08
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04464551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04464551, "The Absorption, Metabolism and Excretion of [14C]D-0316 in Human". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04464551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*